Tonix Pharmaceuticals Presents Data on TNX-801 Mpox Vaccine
Tonix Pharmaceuticals Holding Corp. presented data on TNX-801, a live virus vaccine investigational candidate, at the World Vaccine Congress–Europe 2025.
TNX-801 is designed to provide durable protection against mpox and smallpox, and has demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
The data supports the advancement of TNX-801 toward clinical development. A copy of the presentation, titled Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine, is available on the Tonix website.
TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
Author's summary: Tonix presents TNX-801 vaccine data.
More News
- A confident far-right and a stagnant parliamentary left in the Netherlands - International Viewpoint - online socialist magazine
- An electric debut for new eco-friendly Johns Hopkins buses
- Juric Challenges Lookman To Maintain Positive Attitude With Atalanta
- Why is it so hard to get succession planning right?
- Just how important are set-pieces in FPL?
- Platforms of Extremism: Why Australia Must Confront Digital Misogyny as a Security Threat - Australian Institute of International Affairs
- Everyone watches women’s basketball, even men who belittle it - The Tufts Daily
- When hate masquerades as love – Baptist News Global
- Military archbishop: Army’s cancellation of religious support contracts unfairly harms Catholics - OSV News